Novartis India Ltd vs Parmax Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Novartis India Ltd is ₹ 1021 as of 04 May 11:11 . The P/E Ratio of Novartis India Ltd changed from 65.2 on March 2021 to 19.2 on March 2025 . This represents a CAGR of -21.69% over 5 yearsThe P/E Ratio of Parmax Pharma Ltd changed from 21 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Novartis India Ltd changed from ₹ 1362 crore on March 2021 to ₹ 1938 crore on March 2025 . This represents a CAGR of 7.30% over 5 yearsThe Market Cap of Parmax Pharma Ltd changed from ₹ 13.28 crore on March 2021 to ₹ 15.8 crore on March 2025 . This represents a CAGR of 3.54% over 5 years The revenue of Novartis India Ltd for the Dec '25 is ₹ 94.65 crore as compare to the Sep '25 revenue of ₹ 99.73 crore. This represent the decline of -5.09% The revenue of Parmax Pharma Ltd for the Dec '25 is ₹ 4.33 crore as compare to the Sep '25 revenue of ₹ 2.54 crore. This represent the growth of 70.47% The ebitda of Novartis India Ltd for the Dec '25 is ₹ 31.11 crore as compare to the Sep '25 ebitda of ₹ 33.28 crore. This represent the decline of -6.52% The ebitda of Parmax Pharma Ltd for the Dec '25 is ₹ -0.19 crore as compare to the Sep '25 ebitda of ₹ -1.58 crore. This represent the decline of -87.97% The net profit of Novartis India Ltd changed from ₹ 25.74 crore to ₹ 16.09 crore over 7 quarters. This represents a CAGR of -23.55% The net profit of Parmax Pharma Ltd changed from ₹ 0.01 crore to ₹ -0.73 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Novartis India Ltd changed from 118.09 % on March 2021 to 61.15 % on March 2025 . This represents a CAGR of -12.33% over 5 yearsThe Dividend Payout of Parmax Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

About Parmax Pharma Ltd

Incorporated in Nov.'94, Parmax Pharma Ltd (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
The Company then discontinued their business activities for few years due to various reasons.
Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.

FAQs for the comparison of Novartis India Ltd and Parmax Pharma Ltd

Which company has a larger market capitalization, Novartis India Ltd or Parmax Pharma Ltd?

Market cap of Novartis India Ltd is 2,550 Cr while Market cap of Parmax Pharma Ltd is 11 Cr

What are the key factors driving the stock performance of Novartis India Ltd and Parmax Pharma Ltd?

The stock performance of Novartis India Ltd and Parmax Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Novartis India Ltd and Parmax Pharma Ltd?

As of May 4, 2026, the Novartis India Ltd stock price is INR ₹1032.9. On the other hand, Parmax Pharma Ltd stock price is INR ₹30.02.

How do dividend payouts of Novartis India Ltd and Parmax Pharma Ltd compare?

To compare the dividend payouts of Novartis India Ltd and Parmax Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.